Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

argenx SE Share Price Nasdaq

Equities

ARGX

US04016X1019

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 07:23:25 30/04/2024 pm IST 		5-day change 1st Jan Change
373.9 USD -0.37% Intraday chart for argenx SE -0.48% -1.87%
17/04 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
16/04 Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CI

Financials

Sales 2024 * 1.68B 1.8B 150B Sales 2025 * 2.29B 2.45B 205B Capitalization 20.7B 22.16B 1,848B
Net income 2024 * -137M -147M -12.23B Net income 2025 * 219M 234M 19.55B EV / Sales 2024 * 10.9 x
Net cash position 2024 * 2.31B 2.47B 206B Net cash position 2025 * 2.47B 2.65B 221B EV / Sales 2025 * 7.96 x
P/E ratio 2024 *
-141 x
P/E ratio 2025 *
105 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data

Chart argenx SE

Dynamic Chart

Latest news about argenx SE

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
US Futures, European Stocks Rise After Fed Maintains Outlook DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo... Our Logo
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
More news

Latest transcript on argenx SE

Logo argenx SE
Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024
More transcripts

Analyst Recommendations on argenx SE

Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating MT
Wolfe Research Starts Argenx With Peer Perform Rating MT
More recommendations

Press releases argenx SE

Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease GL
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024 PU
More press releases

News in other languages on argenx SE

Bel20 boven 3.900 punten dankzij zwaargewichten
Brusselse beurs opent voorzichtig hoger
Beursagenda: Belgische bedrijven
Beursagenda: Belgische bedrijven
Groene Brusselse beurs na cijferstroom
More news

Quotes and Performance

1 day-0.37%
1 week-0.48%
Current month-5.19%
1 month-6.05%
3 months-2.06%
6 months-19.57%
Current year-1.87%
More quotes

Highs and lows

1 week
366.72
Extreme 366.72
380.85
1 month
357.55
Extreme 357.55
399.94
Current year
349.86
Extreme 349.86
416.91
1 year
327.73
Extreme 327.725
550.76
3 years
248.21
Extreme 248.21
550.76
5 years
103.75
Extreme 103.75
550.76
10 years
17.33
Extreme 17.33
550.76
More quotes

Managers and Directors - argenx SE

Managers TitleAgeSince
Tim van Hauwermeiren FOU
 Founder 52 01/08/01
Karl Gubitz DFI
 Director of Finance/CFO 54 01/21/01
Filip Borgions CTO
 Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Anthony Adam Rosenberg BRD
 Director/Board Member 71 26/17/26
Joseph deBethizy BRD
 Director/Board Member 74 13/15/13
Pamela Klein BRD
 Director/Board Member 63 28/16/28
More insiders

ETFs positioned on argenx SE

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
1.57% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
1.47% 0 M€ 0.00% -
More ETFs positioned on argenx SE

Quotes

Date Price Change Volume
30/24/30 373.3 -0.53% 3 930
29/24/29 375.3 +0.67% 179,943
26/24/26 372.8 +1.14% 281,322
25/24/25 368.6 -1.71% 305,498
24/24/24 375 -0.02% 266,420

Delayed Quote Nasdaq, April 30, 2024 at 07:07 pm IST

More quotes

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Sector
Biotechnology & Medical Research
Calendar
07/05/2024 - Annual General Meeting
Related indices
STOXX EUROPE 600 (EUR) , BEL-20
More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
348.5 EUR
Average target price
439.3 EUR
Spread / Average Target
+26.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.29% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.49% 96.29B
BIONTECH SE Stock BioNTech SE
-16.07% 21.2B
GENMAB A/S Stock Genmab A/S
-9.72% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.48% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.59% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.30% 12.17B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+307.79% 8.32B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. ARGX Stock